First-Line Pharmacotherapy Approaches for Generalized Anxiety Disorder

被引:56
作者
Davidson, Jonathan R. T. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA
关键词
LONG-TERM TREATMENT; WELL-BEING THERAPY; DOUBLE-BLIND; EXTENDED-RELEASE; PLACEBO; EFFICACY; PREGABALIN; PAROXETINE; SAFETY; TOLERABILITY;
D O I
10.4088/JCP.s.7002.05
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Many patients with generalized anxiety disorder (GAD) do not receive adequate treatment. Several classes of drugs, including benzodiazepines, azapirones, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antihistamines, alpha(2)delta Ca++ channel modulators, and atypical antipsychotics are consistently beneficial in patients with GAD. Cognitive therapy is also effective as a first-line treatment. When individualizing treatment, drug dose ranges and side effect profiles need to be considered, as well as the patient's comorbid conditions. Doses may need to be reduced for elderly or medically ill patients or those taking other medications. Doses may need to be increased for refractory cases. Common comorbid conditions with GAD include depression, alcohol or drug abuse, social anxiety disorder, and panic disorder. In patients with significant depression, an antidepressant is more likely to succeed than a benzodiazepine. Generalized anxiety disorder is a chronic illness that requires long-term treatment. Remission is attainable but can take several months, and stopping medication increases the risk of relapse within the first year of initiating treatment. (J Clin Psychiatry 2009;70[suppl 2]:25-31)
引用
收藏
页码:25 / 31
页数:7
相关论文
共 47 条
[1]   Prevention of relapse in generalized anxiety disorder by escitalopram treatment [J].
Allgulander, Christer ;
Florea, Ioana ;
Huusom, Anna K. Trap .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 (05) :495-505
[2]  
Borkovec TD, 2001, J CLIN PSYCHIAT, V62, P37
[3]   A pilot study of Rhodiola rosea (Rhodax®) for generalized anxiety disorder (GAD) [J].
Bystritsky, Alexander ;
Kerwin, Lauren ;
Feusner, Jamie D. .
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, 2008, 14 (02) :175-180
[4]  
Bystritsky A, 2008, PSYCHOPHARMACOL BULL, V41, P46
[5]  
CHOUINARD G, 2007, ANN M AM COLL NEUR D
[6]   Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial [J].
Davidson, Jonathan R. T. ;
Wittchen, Hans-Ulrich ;
Llorca, Pierre-Michel ;
Erickson, Janelle ;
Detke, Michael ;
Ball, Susan G. ;
Russell, James M. .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 (09) :673-681
[7]   Effectiveness of chromium in atypical depression: A placebo-controlled trial [J].
Davidson, JRT ;
Abraham, K ;
Connor, KM ;
McLeod, MN .
BIOLOGICAL PSYCHIATRY, 2003, 53 (03) :261-264
[8]   ALPRAZOLAM VERSUS BUSPIRONE IN THE TREATMENT OF OUTPATIENTS WITH GENERALIZED ANXIETY DISORDER [J].
ENKELMANN, R .
PSYCHOPHARMACOLOGY, 1991, 105 (03) :428-432
[9]   Well-being therapy of generalized anxiety disorder [J].
Fava, GA ;
Ruini, C ;
Rafanelli, C ;
Finos, L ;
Salmaso, L ;
Mangelli, L ;
Sirigatti, S .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2005, 74 (01) :26-30
[10]   Cognitive behavior approach to loss of clinical effect during long-term antidepressant treatment: A pilot study [J].
Fava, GA ;
Ruini, C ;
Rafanelli, C ;
Grandi, S .
AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (12) :2094-2095